Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility
Authors
Fankhauser, C. D.Afferi, L.
Stroup, S. P.
Rocco, N. R.
Olson, K.
Bagrodia, A.
Baky, F.
Cazzaniga, W.
Mayer, E.
Nicol, D.
Islamoglu, E.
de Vergie, S.
Saoud, R.
Eggener, S. E.
Nazzani, S.
Nicolai, N.
Hugar, L.
Sexton, W. J.
Matei, D. V.
De Cobelli, O.
Cheaib, J.
Pierorazio, P. M.
Porter, J.
Hermanns, T.
Hamilton, R. J.
Hiester, A.
Albers, P.
Clarke, N.
Mattei, A.
Issue Date
2022
Metadata
Show full item recordAbstract
Purpose To describe the perioperative safety, functional and immediate post-operative oncological outcomes of minimally invasive RPLND (miRPLND) for testis cancer. Methods We performed a retrospective multi-centre cohort study on testis cancer patients treated with miRPLND from 16 institutions in eight countries. We measured clinician-reported outcomes stratified by indication. We performed logistic regression to identify predictors for maintained postoperative ejaculatory function. Results Data for 457 men undergoing miRPLND were studied. miRPLND comprised laparoscopic (n = 56) or robotic (n = 401) miRPLND. Indications included pre-chemotherapy in 305 and post-chemotherapy in 152 men. The median retroperitoneal mass size was 32 mm and operative time 270 min. Intraoperative complications occurred in 20 (4%) and postoperative complications in 26 (6%). In multivariable regression, nerve sparing, and template resection improved ejaculatory function significantly (template vs bilateral resection [odds ratio (OR) 19.4, 95% confidence interval (CI) 6.5–75.6], nerve sparing vs non-nerve sparing [OR 5.9, 95% CI 2.3–16.1]). In 91 men treated with primary RPLND, nerve sparing and template resection, normal postoperative ejaculation was reported in 96%. During a median follow-up of 33 months, relapse was detected in 39 (9%) of which one with port site (< 1%), one with peritoneal recurrence and 10 (2%) with retroperitoneum recurrences. Conclusion The low proportion of complications or peritoneal recurrences and high proportion of men with normal postoperative ejaculatory function supports further miRPLND studies.Citation
Fankhauser CD, Afferi L, Stroup SP, Rocco NR, Olson K, Bagrodia A, et al. Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World Journal of Urology. Springer Science and Business Media LLC; 2022.Journal
World Journal of UrologyDOI
10.1007/s00345-022-03974-9PubMed ID
35279732Additional Links
https://dx.doi.org/10.1007/s00345-022-03974-9Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1007/s00345-022-03974-9
Scopus Count
Collections
Related articles
- Robot-assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer: Evolution of the Technique.
- Authors: Stepanian S, Patel M, Porter J
- Issue date: 2016 Oct
- [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
- Authors: Li XD, Guo SJ, Chen SL, Liu ZF, Dong P, Zhang ZL, Jiang LJ, Yao K, Li YH, Han H, Qin ZK, Liu ZW, Zhou FJ
- Issue date: 2017 Aug 1
- Outcomes of post-chemotherapy robot-assisted retroperitoneal lymph node dissection in testicular cancer: multi-institutional study.
- Authors: Abdul-Muhsin H, Rocco N, Navaratnam A, Woods M, L'Esperance J, Castle E, Stroup S
- Issue date: 2021 Oct
- Robotic retroperitoneal lymph node dissection for primary and post-chemotherapy testis cancer.
- Authors: Nason GJ, Kuhathaas K, Anson-Cartwright L, Jewett MAS, O'Malley M, Sweet J, Hansen A, Bedard P, Chung P, Hahn E, Warde P, Hamilton RJ
- Issue date: 2022 Apr
- Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
- Authors: Steiner H, Leonhartsberger N, Stoehr B, Peschel R, Pichler R
- Issue date: 2013 Jun